• KPT330 Enhances CRISPR-Cas9 Precision via mRNA Nuclear Expor

  2026-04-28

  The referenced study demonstrates that the FDA-approved drug KPT330 improves the specificity of CRISPR-Cas9 genome and base editing by selectively inhibiting the nuclear export of Cas9 mRNA, offering a novel, indirect mechanism to mitigate off-target effects. This approach expands the genome editing toolbox and may inform safer, more controlled applications in mammalian systems.

• Batimastat (BB-94): Transforming Translational MMP Inhibitio

  2026-04-28

  This thought-leadership article provides translational researchers with a deep mechanistic understanding of matrix metalloproteinase (MMP) inhibition using Batimastat (BB-94), explores strategic considerations for experimental design, and highlights recent findings on the nuanced regulation of neurotrophic factors at the neuromuscular junction. By connecting emerging insights from basic neurobiology to cancer research, this article advances the conversation beyond standard product pages, outlining both the opportunities and limitations for cross-domain application.

• Lenalidomide (CC-5013): Applied Protocols & Innovation in My

  2026-04-27

  Harnessing Lenalidomide (CC-5013) as an immune system activation agent unlocks new experimental synergies in multiple myeloma research, especially when paired with epigenetic modulation. This guide delivers actionable workflows, advanced troubleshooting, and data-driven insights to help researchers maximize reproducibility and translational impact with APExBIO’s trusted reagent.

• Methyl-β-cyclodextrin: Technical Guidance for Membrane Studi

  2026-04-27

  Methyl-β-cyclodextrin facilitates the selective extraction of cholesterol and related lipids from cell membranes, supporting studies of membrane fluidity, lipid raft integrity, and cholesterol-dependent signaling pathways. It is intended strictly for research workflows and should not be applied in diagnostic or therapeutic settings. Adherence to storage, solubilization, and handling guidance is critical for experimental success.

• Miltefosine: Applied Protocols for PI3K/Akt Pathway and Neut

  2026-04-26

  Miltefosine, a unique dual-pathway modulator, enables advanced workflows in both cancer and hematology research. This guide translates cutting-edge findings—including Ras/MEK/ERK-driven neutrophil differentiation—into actionable experimental strategies, troubleshooting advice, and optimization tips for maximizing data quality.

• TPCA-1 (A4602): Reliable IKK-2 Inhibition for Cell Assays

  2026-04-25

  This article addresses key laboratory challenges in cell viability, proliferation, and cytotoxicity assays, demonstrating how TPCA-1 (SKU A4602) enables reproducible, data-driven NF-κB pathway inhibition. Drawing on scenario-based Q&A, validated protocols, and comparative vendor analysis, we show why TPCA-1 is a trusted IKK-2 inhibitor for inflammation research workflows.

• Annexin V in Immune Imbalance: Strategic Leverage for Transl

  2026-04-24

  This thought-leadership article explores the mechanistic basis and strategic application of human recombinant Annexin V as a phosphatidylserine binding protein in translational research. Drawing on recent immunological discoveries, including miR-519d-3p’s role in preeclampsia, it offers actionable protocol guidance and competitive landscape analysis for apoptosis assays in immune dysregulation. The discussion integrates references to APExBIO’s Annexin V, expanding beyond standard assay guides to chart new directions in cell death research and immune tolerance models.

• Catalpol’s Multifaceted Protection in Cardio-Cerebrovascular

  2026-04-24

  This review comprehensively evaluates catalpol, an iridoid glucoside, for its protective effects against cardio-cerebrovascular diseases (CVDs). The paper synthesizes recent mechanistic and preclinical findings, emphasizing catalpol’s antioxidant, anti-inflammatory, and antiapoptotic activities, and highlights the need for further translational and clinical research.

• TMRE Mitochondrial Membrane Potential Assay Kit: Precision &

  2026-04-23

  The TMRE mitochondrial Membrane Potential Assay Kit (APExBIO, K2233) enables high-throughput, quantitative analysis of mitochondrial health and apoptosis via a robust, fluorescence-based workflow. Leveraging the latest mechanistic insights into sodium-driven mitochondrial dysfunction, this kit empowers researchers to dissect energy metabolism and cell fate with unprecedented sensitivity and reliability.

• Tioconazole: Molecular Insights and Next-Gen Antifungal Mode

  2026-04-23

  Explore Tioconazole as a benchmark antifungal medication—this article uncovers its molecular action, rigorous research applications, and translational insights that advance antifungal drug development beyond standard protocols.

• Plk1 Regulation of p31comet in Mitotic Checkpoint Disassembl

  2026-04-22

  This study reveals how Polo-like kinase 1 (Plk1) directly phosphorylates and inhibits the Mad2-binding protein p31comet, limiting its ability to disassemble mitotic checkpoint complexes. The findings clarify the molecular coordination that ensures proper chromosome segregation during mitosis and provide new insights into regulatory mechanisms of cell cycle progression.

• Spermine Tetrahydrochloride: Protocols and Innovations for P

  2026-04-22

  Spermine tetrahydrochloride sets a new benchmark for reproducible membrane protection, protein crystallization, and nanoparticle crosslinking workflows. Leveraging its charge-based interactions, it delivers superior stability and activity retention in challenging biological and material science assays—outperforming related polyamines and enabling translational advances in both neuroscience and nanomedicine.

• Indole-3-pyruvic Acid Mitigates RA via Aryl Hydrocarbon Rece

  2026-04-21

  This study demonstrates that indole-3-pyruvic acid (IPA), a tryptophan-derived metabolite, alleviates rheumatoid arthritis (RA) by modulating the Th17/Treg cell balance through activation of the aryl hydrocarbon receptor (AhR) pathway. The findings provide mechanistic evidence for IPA as a potential immunomodulatory agent in RA, with practical implications for translational research.

• Caspofungin: Lipopeptide Antifungal Drug for β-Glucan Inhibi

  2026-04-21

  Caspofungin is a selective lipopeptide antifungal drug that inhibits β-1,3-glucan synthase, disrupting fungal cell wall biosynthesis. This agent demonstrates potent efficacy against azole-resistant Candida, with benchmarked IC50 and MIC90 values in laboratory models. Its application in antifungal therapeutics research is supported by robust protocols and comparative studies.

• Ibrexafungerp and Caspofungin: Efficacy Against Resistant Ca

  2026-04-20

  Wiederhold et al. demonstrate that ibrexafungerp exhibits potent in vitro and in vivo activity against fluconazole-resistant Candida auris, even with delayed therapy initiation. The study provides critical protocol and efficacy data for antifungal agents targeting the β-(1,3)-D-glucan biosynthesis pathway, with practical benchmarks for research on azole-resistant Candida infections.

15631 records 1/1043 page Next 12345 下5页 Last page